|
Merck
& Co., Inc. on September 30, 2004 announced a
voluntary worldwide withdrawal of VIOXX® (rofecoxib),
its arthritis and acute pain medication. The company’s
decision is based on a three-year data from a
prospective, randomized, placebo-controlled clinical
trial, the APPROVe (Adenomatous Polyp Prevention on
VIOXX) trial.
The trial was designed
to evaluate the efficacy of VIOXX 25 mg in preventing
recurrence of colorectal polyps in patients with a
history of colorectal adenomas. In this study, there was
an increased relative risk for confirmed cardiovascular
events, such as heart attack and stroke, beginning after
18 months of treatment in the patients taking VIOXX
compared to those taking placebo. The results for the
first 18 months of the APPROVe study did not show any
increased risk of confirmed cardiovascular events on
VIOXX, and in this respect, are similar to the results
of two placebo-controlled studies described in the
current U.S. labeling for VIOXX.
"We
are taking this action because we believe it best serves
the interests of patients," the chairman, president
and chief executive officer of Merck, Raymond V.
Gilmartin, said in a statement on the New Jersey
company's Web site.
"Although
we believe it would have been possible to continue to
market Vioxx with labeling that would incorporate these
new data, given the availability of alternative
therapies, and the questions raised by the data, we
concluded that a voluntary withdrawal is the responsible
course to take." |